secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106536
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M
------------------------------------------------------------

- Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.
- Cash $34.7M; private placement raised ~$11.5M upfront at >10% premium, potential $10.4M from warrants.
- Q2 net loss $16.1M ($0.34/shr); R&D $6.6M, G&A $3.3M; cash runway into Q2 2026.
- Strategic relationship with Option Care Health (OPCH) to support U.S. commercial launch of eDSP.
- New SAB member Dr. Hassan Abolhassani appointed; Phase 2 DMD study design finalized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/0000950170-25-106536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/qncx-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer